The effects of sodium‐glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions
Abstract Sodium‐glucose cotransporter 2 (SGLT2) inhibitors are a unique class of oral anti‐
hyperglycaemic medications that act to reduce glucose reabsorption in the renal proximal …
hyperglycaemic medications that act to reduce glucose reabsorption in the renal proximal …
Emergence of SGLT2 inhibitors as powerful antioxidants in human diseases
KF Tsai, YL Chen, TTY Chiou, TH Chu, LC Li, HY Ng… - Antioxidants, 2021 - mdpi.com
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a new class of oral glucose-lowering
agents. Apart from their glucose-lowering effects, large clinical trials assessing certain …
agents. Apart from their glucose-lowering effects, large clinical trials assessing certain …
Randomized trial of empagliflozin in nondiabetic patients with heart failure and reduced ejection fraction
CG Santos-Gallego, AP Vargas-Delgado… - Journal of the American …, 2021 - jacc.org
Background Large clinical trials established the benefits of sodium-glucose cotransporter 2
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
inhibitors in patients with diabetes and with heart failure with reduced ejection fraction …
Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics
CG Santos-Gallego, JA Requena-Ibanez… - Journal of the American …, 2019 - jacc.org
Background: Empagliflozin cardiac benefits in the EMPA-REG OUTCOME (Empagliflozin
Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be …
Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) trial cannot be …
Mechanistic insights of empagliflozin in nondiabetic patients with HFrEF: from the EMPA-TROPISM study
JA Requena-Ibáñez, CG Santos-Gallego… - Heart Failure, 2021 - jacc.org
Objectives The goal of this study was to evaluate the effect of empagliflozin, in addition to
optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis …
optimal medical treatment, on epicardial adipose tissue (EAT), interstitial myocardial fibrosis …
Empagliflozin ameliorates diastolic dysfunction and left ventricular fibrosis/stiffness in nondiabetic heart failure: a multimodality study
CG Santos-Gallego, JA Requena-Ibanez… - Cardiovascular …, 2021 - jacc.org
Objectives The purpose of this study was to investigate the effect of empagliflozin on
diastolic function in a nondiabetic heart failure with reduced ejection fraction (HFrEF) …
diastolic function in a nondiabetic heart failure with reduced ejection fraction (HFrEF) …
Effects of glucagon‐like peptide‐1 receptor agonists, sodium‐glucose cotransporter‐2 inhibitors, and their combination on endothelial glycocalyx, arterial function, and …
I Ikonomidis, G Pavlidis, J Thymis, D Birba… - Journal of the …, 2020 - Am Heart Assoc
Background We investigated the effects of insulin, glucagon‐like peptide‐1 receptor
agonists (GLP‐1 RA), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), and their …
agonists (GLP‐1 RA), sodium‐glucose cotransporter‐2 inhibitors (SGLT‐2i), and their …
Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a …
Y Takaoka, T Suzuki, D Yoneoka… - Cochrane Database …, 2021 - cochranelibrary.com
Background Cardiovascular disease (CVD) is a leading cause of death globally. Recently,
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …
dipeptidyl peptidase‐4 inhibitors (DPP4i), glucagon‐like peptide‐1 receptor agonists (GLP …
Dapagliflozin improves left ventricular remodeling and aorta sympathetic tone in a pig model of heart failure with preserved ejection fraction
N Zhang, B Feng, X Ma, K Sun, G Xu… - Cardiovascular diabetology, 2019 - Springer
Background Heart failure with preserved ejection fraction (HFpEF) is a difficult disease with
high morbidity and mortality rates and lacks an effective treatment. Here, we report the …
high morbidity and mortality rates and lacks an effective treatment. Here, we report the …
Effect of sodium–glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta …
YW Yu, XM Zhao, YH Wang, Q Zhou, Y Huang… - Cardiovascular …, 2021 - Springer
Background Although the benefits of sodium–glucose cotransporter 2 inhibitors (SGLT2i) on
cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) …
cardiovascular events have been reported in patients with type 2 diabetes mellitus (T2DM) …